Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19223898 | 0.83 | CYP1A2 (0.46) | HRH3KMT2ACYP1A2MEN1ALDH1A1 | |
| SCHEMBL1991044 | 0.83 | CYP1A2 (0.47) | HRH3CYP1A2 | |
| SCHEMBL23561249 | 0.82 | HRH3 (0.51) | HRH3KMT2ABLMMEN1ALDH1A1 | |
| SCHEMBL27648358 | 0.82 | KDM4E (0.33) | HRH3CYP1A2 | |
| SCHEMBL24368020 | 0.80 | HRH3 (0.57) | HRH3KMT2ABLMHSD11B1MEN1 | |
| SCHEMBL21121000 | 0.79 | HRH3 (0.38) | HRH3ALDH1A1 | |
| SCHEMBL23561209 | 0.79 | ALDH1A1 (0.53) | KMT2AMEN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL20466537 | 0.79 | HRH3 (0.56) | HRH3KMT2AHSD11B1MEN1ALDH1A1 | |
| SCHEMBL23643498 | 0.79 | HRH3 (0.43) | HRH3KMT2A | |
| SCHEMBL12871784 | 0.79 | HRH3 (0.43) | HRH3KMT2ACYP1A2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163508-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | HRH3 69/4885KMT2A 404/4885CYP1A2 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.